Inovio completes enrolment in mid-stage U.S. study of COVID-19 vaccine - (Financial Post via NewsPoints Desk)

  • Inovio Pharmaceuticals says it has completed Phase II enrolment for a mid-to-late stage US trial of its COVID-19 vaccine candidate INO-4800, as reported in the Financial Post.

  • Last September, the FDA a put on hold the Phase III portion of the US study of INO-4800 as it sought more information on the device used to inject the vaccine.

  • Inovio said it was actively working to address FDA's concerns and plans to respond in May.

  • The company is also developing next-generation COVID-19 vaccine candidates that could be tailored to known and potentially unknown SARS-CoV-2 variants.

To read more NewsPoints articles, click here.